Impact of Individual Radiosensitivity on Late Toxicities of Radiosurgery in Essential Trigeminal Neuralgia
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NICE · Mar 3, 2025
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how individual sensitivity to radiation affects the side effects that patients experience after undergoing a specific type of treatment called radiosurgery for trigeminal neuralgia, which is a condition that causes severe facial pain. The researchers want to see if a simple blood test, which measures how sensitive a person's cells are to radiation, can help predict who might be more likely to experience complications after treatment. This could potentially lead to adjustments in treatment plans to reduce risks for those identified as sensitive.
To participate in the trial, individuals must be at least 18 years old and have had radiosurgery for trigeminal neuralgia at a specific hospital over a year ago. They should not have previously undergone other invasive treatments for their pain, and certain medical conditions, like multiple sclerosis, would exclude them from the study. If eligible, participants will provide a blood sample for the sensitivity test and may receive tailored recommendations based on their results, which could help guide their treatment options moving forward.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients ≥ 18 years of age
- • Patients treated for trigeminal neuralgia by radiosurgery at CHPG more than 12 months ago
- • Treatment of the nerve with a 4 or 5 mm cone
- • Patient affiliated to social security
- • Patient agreement: obtaining the patient's non-opposition (France) or consent (Monaco)
- Exclusion Criteria:
- • Patients pre-treated for neuralgia by another invasive method: thermo coagulation, decompression surgery, radiosurgery...
- • Patients with multiple sclerosis (MS)
- • Secondary neuralgia
- • Hypoesthesia pre-existing treatment
- • Protected persons: persons deprived of their liberty, patients under guardianship or trusteeship
About Centre Hospitalier Universitaire De Nice
The Centre Hospitalier Universitaire (CHU) de Nice is a leading academic medical center located in Nice, France, dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHU de Nice is committed to enhancing patient care by conducting rigorous studies that explore new therapies and treatment modalities across various medical disciplines. With a focus on collaboration, the center integrates cutting-edge technology and interdisciplinary expertise to ensure the highest standards of research integrity and patient safety. CHU de Nice plays a vital role in the development of evidence-based medicine, contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Monaco, , Monaco
Nice, Alpes Maritimes, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported